Your search for oral corticosteroids returned 7 results

AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.

Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).

The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.

The BLA submission is supported by data from the PATHFINDER clinical program.

Acton announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for its new asthma product, Aerospan (flunisolide HFA, 80 mcg) Inhalation Aerosol.

Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company’s LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.

Santarus announced pooled data from two Phase 3 studies of Uceris (budesonide MMX) for the induction of remission of mild or moderate active ulcerative colitis.